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ARTICLE
Timed inhibition of CDC7 increases CRISPR-Cas9
mediated templated repair
Beeke Wienert 1,2,3,12, David N. Nguyen 4,5,6,12, Alexis Guenther 7, Sharon J. Feng1,2, Melissa N. Locke 2,
Stacia K. Wyman 1, Jiyung Shin8, Katelynn R. Kazane1,2, Georgia L. Gregory 3, Matthew A. M. Carter3,
Francis Wright4, Bruce R. Conklin3,9, Alex Marson 1,4,5,6,10,11, Chris D. Richardson 1,2,7✉ &
Jacob E. Corn 1,2,8✉
Repair of double strand DNA breaks (DSBs) can result in gene disruption or gene mod-
ification via homology directed repair (HDR) from donor DNA. Altering cellular responses to
DSBs may rebalance editing outcomes towards HDR and away from other repair outcomes.
Here, we utilize a pooled CRISPR screen to define host cell involvement in HDR between a
Cas9 DSB and a plasmid double stranded donor DNA (dsDonor). We find that the Fanconi
Anemia (FA) pathway is required for dsDonor HDR and that other genes act to repress HDR.
Small molecule inhibition of one of these repressors, CDC7, by XL413 and other inhibitors
increases the efficiency of HDR by up to 3.5 fold in many contexts, including primary T cells.
XL413 stimulates HDR during a reversible slowing of S-phase that is unexplored for Cas9-
induced HDR. We anticipate that XL413 and other such rationally developed inhibitors will be
useful tools for gene modification.
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Genome editing with targeted nucleases, such as CRISPR-Cas9, is a powerful tool for research and a promisingapproach for therapeutic treatment of human disease.
One strategy for efficient genome editing in eukaryotic cells
introduces a ribonucleotide protein (RNP) complex comprised of
the type II endonuclease Cas9 and a guide RNA (gRNA), which
create a double strand DNA break (DSB) at a targeted location in
the genome1,2. This DSB is repaired by cellular DNA repair
pathways to produce two outcomes: error-prone sequence dis-
ruption by insertion or deletion (indels) at the DSB, or precise
sequence modification via homology directed repair (HDR) that
copies donor DNA sequences into the DSB. The targeted incor-
poration of exogenous DNA sequences enables multiple new
research avenues in metazoan cells, including endogenous epitope
tagging and the insertion of SNPs to test disease causation, and
using these techniques in human tissues could enable therapeutics
to correct genetic lesions that drive human disease3,4. Strategies to
favor precise HDR outcomes over deleterious error-prone repair
in human cells are therefore of intense interest both to improve
understanding of biological pathways and enable new therapeutic
options.
Human cells have multiple overlapping DSB repair pathways
that have been implicated in Cas9-mediated gene modification5–7
such as alternative-end joining, synthesis-dependent strand
annealing, and HDR, which encompasses multiple different
mechanisms of repair. To investigate the various HDR mechan-
isms in greater detail, we previously developed a reporter8 that
allowed us to interrogate the genetic requirements of Cas9-
mediated HDR using single-stranded donor DNA (ssDonor) and
discovered that single strand template repair (SSTR) requires the
Fanconi Anemia (FA) DNA repair pathway9. We furthermore
found that SSTR does not depend on the classic RAD51 pathway,
unlike homologous recombination (HR) repair from a double
stranded DNA donor (dsDonor). These distinct requirements for
HDR from ssDonor and dsDonor implied that different donors
produce molecularly identical gene modifications via different
mechanistic routes. To more completely map how different types
of donors mediate Cas9-induced HDR, we used genetic screening
to reveal the DNA repair factors that are involved in HR using a
dsDonor. Here, we describe genes that upregulate or down-
regulate HR from dsDonor templates, finding pathways that are
both shared with and distinct from SSTR. We furthermore
investigate factors whose knockdown increases Cas9-induced
HDR, discovering that timed administration of a small molecule
inhibitor of one of these factors, cycle 7-related protein kinase
(CDC7), increases HR and SSTR by up to 3.5-fold in multiple
contexts including primary human T cells.
Results
Cas9-induced SSTR and HR overlap, with key distinctions. We
adapted a previously described pooled screening platform9 to
define the individual contribution made by each of thousands of
genes to Cas9-mediated gene replacement using a dsDonor
plasmid template. The basis of this platform is the stable
expression of three components in each cell: (1) a dCas9-KRAB
CRISPRi construct10, (2) a BFP reporter gene8, and (3) a gRNA
targeting the transcription start site (TSS) of a single gene. We
constructed a gRNA library to target genes with Gene Ontology
(GO) terms related to DNA, comprising a library of approxi-
mately 2000 genes at a density of five guides per TSS11. Pooled
K562 erythroleukemia cell populations stably expressing BFP and
individually downregulating a specific gene were transiently
nucleofected with a Cas9 RNP targeted to introduce a DSB in the
BFP reporter, together with a dsDonor plasmid with a GFP
sequence template that converts BFP to GFP upon successful HR8
(Fig. 1a). Edited cell populations were separated by fluorescence-
activated cell sorting (FACS) (HR: BFP−GFP+; gene disruption:
BFP−GFP−) (Supplementary Fig. 1a), and gRNA frequency in
each population was determined by sequencing the stably inte-
grated gRNA cassette. Genes whose upregulation and down-
regulation altered each repair outcome were determined by
comparing the sorted populations to the edited but unsorted cell
population. Similarities between the reagents and techniques used
in this screening approach permitted direct comparison with our
earlier screen editing the same locus but utilizing a ssDonor9
(Fig. 1a).
Guide RNAs targeting genes that restrict HR were enriched in
the BFP− GFP+ population (because their knockdown favors
HR), while gRNAs targeting genes that are required for HR were
depleted in the BFP− GFP+ population (Fig. 1b). As expected,
classic HR factors such as BRCA1, BARD1, RAD50, and NBN
were genetically required for Cas9-mediated repair from a
plasmid dsDonor, and these often were found in the same
physical complexes with one another in the STRING protein
database12 (Fig. 1c). Our prior work defined the Fanconi Anemia
(FA) pathway as necessary for Cas9-mediated SSTR9, and we now
report that almost the entire FA repair pathway is also required
for Cas9-induced HR. 31 of 40 FA and FA-related genes were
required for HR, suggesting that this is an activity of the overall
FA pathway (Supplementary Fig. 1b) and indicating its
importance for all forms of Cas9-mediated HDR13.
The shared reliance of Cas9-induced SSTR and HR on the FA
pathway motivated us to systematically explore the overlapping
genetic dependencies of HDR from single and double stranded
templates. We performed GO term analysis14 on statistically
significant (p < 0.05) genes involved in SSTR and HR to define
pathways involved in each process (Supplementary Fig. 1c and
Supplementary Data 1 GO Terms). There was substantial overlap
between SSTR and HR: both pathways require Fanconi Anemia
Repair, nucleotide excision repair (NER), and strand displace-
ment activities, which is driven by mutual reliance on FA
proteins, members of the TFIIH complex, and the BLM helicase.
Both SSTR and HR may therefore challenge cells to balance NER-
like single strand editing activities with templated repair events, as
has been suggested for repair of interstrand crosslinks15. Despite
these similarities, SSTR and HR are distinct in notable ways.
SSTR but not HR is associated with Negative regulation of
transposition, a GO term including our SSTR hits APOBEC3C,
D, F, and G. Originally reported as RNA editing enzymes, these
enzymes are known to modify ssDNA during gene editing
reactions16, and similar proteins have been repurposed as
targeted DNA base-editing reagents17. HR on the other hand
depends on genes involved in Double Strand Break Repair via
Homologous Recombination, which includes factors that potenti-
ate meiotic homologous recombination (Supplementary Fig. 1c).
These observations suggest that all HDR requires the FA pathway,
but the HR and SSTR mechanisms each require specialized
activities to respond to donor topologies or intermediate
structures specific to each repair process.
We identified several genes that normally repress HR, such that
their knockdown enhances HR efficiency (Fig. 1b). Some of these
genes are consistent with a model in which NHEJ and HR
compete to repair DSBs, so inhibition of one pathway favors the
other18–20. Examples of these repressor genes include TP53-
binding protein 1 (53BP1), X-ray repair cross-complementing
protein 4 (XRCC4) and non-homologous end joining factor 1
(NHEJ1), which interact at DSBs to promote DNA ligase 4 (LIG4)
association during non-homologous end-joining (NHEJ)21. Other
repressors identified here have not previously been reported to
increase HR efficiency, but have roles in processes that have been
linked to DNA repair outcomes such as cell cycle progression.
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Fig. 1 A pooled CRISPR screen reveals pathways that regulate templated repair using Cas9-RNP and a plasmid dsDonor. a Schematic showing BFP→
GFP CRISPRi screening strategy. Pooled K562-CRISPRi cells that stably express BFP and a library of gRNAs targeting DNA metabolism genes are further
edited with Cas9-RNP that cuts within BFP and a plasmid dsDonor template that contains a promoterless copy of GFP. Cas9 gene editing results in three
populations: Unedited (BFP+GFP−), Indel (BFP−GFP−), and HR (BFP−GFP+). Guide RNA frequencies in the HR population were quantified and compared
to the unsorted population to identify genes that promote/restrict HR. These genes were compared to data from a prior screen using ssDNA donor8.
b Genes regulating dsDonor HR. A volcano plot of pooled screen hits showing the Fanconi Anemia pathway (blue) and HR repressors with available small
molecule inhibitors (orange). Data presented from n= 2 screen replicates. c Genetic regulators of HR participate in physical interactions with one another.
Significant (p < 0.005, Mann–Whitney test) hits that impacted HR were cross-referenced with the STRING protein interaction database12. Factors involved
in homologous recombination (HR, red) or Fanconi Anemia (FA, blue) pathways were identified by GO term. Only regulators appearing in the screen and
having at least one interaction with another screening hit are shown.
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These proteins include CDC7, polo-like kinase 1 (PLK1), E2F
transcription factor 1 (E2F1), and polo-like kinase 3 (PLK3).
Inhibiting HR repressors increases both HR and SSTR. HR is
quite inefficient in human cells yet desirable for its ability to
precisely engineer genomic sequences and even insert long (>500
bp) sequences such as epitope tags or ORF replacements22. Our
exploration of genes that regulate HR presented us with a number
of candidate repressors whose knockdown would increase HR
efficiency. However, gene editing is frequently performed in
primary cell types or other experimental contexts where tran-
scriptional or genetic repression is unsuitable. Thus, small
molecule treatments that increase HR would be more desirable
because they can be administered in a variety of settings and
easily withdrawn. We selected genes that repress SSTR, HR, or
both and performed an extensive literature search to find small
molecule inhibitors of these HDR repressors (Fig. 1b). We
focused on eight commercially available small molecules that are
reported to inhibit CCND1, CDC7, HIPK2, MAPK14, NOX4,
PLK3, PLK1, and 53BP1 (Supplementary Fig. 1d).
We first asked if chemical inhibition of these HR repressors
affects HR or SSTR editing outcomes using our K562 cell line
stably expressing the BFP-to-GFP HDR reporter system8.
Reporter cells were nucleofected with a Cas9 RNP targeting the
BFP reporter gene and either a ssDonor or plasmid dsDonor. We
reasoned that small molecule inhibition of HR repressors would
be most effective during gene editing (e.g., post-treatment), so we
treated cells with different inhibitors for 24 h and then recovered
in inhibitor-free media (Fig. 2a). BFP-to-GFP HDR outcomes
were monitored by flow cytometry after four days (Supplemen-
tary Fig. 2a). Many compounds resulted in no change or even a
reduction of HR, which could be caused by impaired cell fitness.
Inhibition of mitogen-activated protein kinase 14 (MAPK14)
with SB220025 slightly enhanced SSTR (1.1-fold), and inhibition
of PLK3 with GW843682X slightly increased both SSTR and HR
from the plasmid dsDonor (1.1-fold and 1.2-fold).
By contrast, treatment with the CDC7 inhibitor XL41323
resulted in a significant increase in both SSTR and HR (1.4-fold
and 1.8-fold, p < 0.0001) (Fig. 2b). siRNA inhibition of CDC7 was
less effective at promoting HR (1.4-fold) than small molecule
inhibition (Supplementary Fig. 2b, c), which suggests that
inactivating CDC7 kinase activity may be more effective than
reducing its overall levels. The effect of XL413 is concentration
dependent, as both SSTR and HR increase in a dose-dependent
manner, with 33 μM XL413 increasing HDR 1.8-fold to 2.1-fold
(Fig. 2c). XL413 concentrations up to 10 μM and exposure for up
to 24 h did not result in a notable decrease in viability in K562
cells (Supplementary Fig. 2d, e), and we therefore used 10 μM
XL413 in subsequent experiments unless noted otherwise. To
optimize CDC7 inhibition, we explored if different timing of
exposure to XL413 (e.g., pre-treatment) altered HDR rates.
However, pre-exposure to XL413 and then release during editing
resulted in reduced levels of HDR, while pre-exposure and post-
exposure did not significantly increase HDR over post-treatment
alone (Fig. 2d, e). We therefore conclude that the optimal timing
for HDR is to incubate edited cells immediately post-treatment in
media containing CDC7 inhibitors.
CDC7 inhibition increases HDR at multiple endogenous loci.
We next asked if XL413’s ability to stimulate HDR is generally
applicable to multiple genomic loci and HDR cargo sizes. We used
Cas9-induced HR from a plasmid dsDonor template to knock-in a
GFP coding sequence at the C-terminus of various genes in K562
cells using editing reagents previously developed as part of
a comprehensive cell-tagging effort24: Lysosomal-associated
membrane protein 1 (LAMP1), fibrillarin (FBL), histone H2BJ
(HIST1H2BJ), nucleophosmin (NPM1), Structural maintenance of
chromosomes protein 1 A (SMC1A), RNA binding protein FUS
(FUS), and translocase of outer mitochondrial membrane 20
(TOMM20). We found that treatment with XL413 for 24 h
immediately after nucleofection increased the HR efficiency at all
loci, ranging from 1.6-fold to 3.5-fold irrespective of the original
frequency of HR (Fig. 3a and Supplementary Fig. 3a). Importantly,
the frequency of HR remained unchanged over two weeks of cell
culture, indicating that edits produced during XL413 treatment are
stable over long time periods.
We then investigated if SSTR is similarly increased by CDC7
inhibition at endogenous loci. We designed two ssDonor editing
strategies: insertions of a 2 × FLAG-tag at the C-terminus of
TOMM20 (Supplementary Fig. 3b), and SNP modifications at five
different genomic loci. Using amplicon PCR and next-generation
sequencing, we found that XL413-treated K562 cells had up to a
2.5-fold increase in SSTR-based FLAG tagging and introduction
of SNPs relative to untreated cells (Fig. 3b, c and Supplementary
Data 2). Genomic increases in tagging corresponded with
increased ability to detect FLAG-tagged TOMM20 by Western
blotting (Supplementary Fig. 3c, d). These findings suggest that
CDC7 inhibition robustly increases SSTR and HR, and can be
used to increase the frequency of both single nucleotide
substitutions and larger endogenous gene tagging.
CDC7 inhibition enhances HDR in primary cells. HDR in
primary cells is a long-standing goal of gene editing, both for its
ability to correct disease-causing SNPs and to deliver large pay-
loads such as chimeric antigen receptors22,25. We therefore
investigated the ability of XL413 to increase HR in human T cells
derived from peripheral blood mononuclear cells (PBMCs) of
healthy donors. We performed gene editing using RNPs targeting
the RAB11A, TUBA1B, and CLTA loci, together with linear
dsDonor templates for each locus to generate fluorescently-tagged
protein fusions (GFP, mCherry, or BFP)22. XL413 treatment after
editing produced a dose-dependent increase in HR efficiency at
each locus in T cells (Fig. 4a), without evidence of decreased
viability (Supplementary Fig. 4a). Using a ssDonor template and
targeting five additional genomic loci, we found that XL413 also
boosts SSTR in human T cells while NHEJ frequencies decreased
(Fig. 4b and Supplementary Data 2). This shows that CDC7
inhibition does not affect the total amount of editing but rather
shifts the ratio of edited alleles from NHEJ to HDR. Furthermore,
treatment with XL413 increased SSTR beyond 60% efficiency
when introducing a naturally occurring SNP that alters recogni-
tion of CD4 by the OKT4 antibody without affecting recognition
by the SK3 antibody26 (Fig. 4c and Supplementary Fig. 4b–d).
Reversal of pathogenic mutations in patient-derived stem cells
is a promising therapeutic application of HDR27,28. We therefore
tested XL413 in primary human hematopoietic stem and
progenitor cells (HSPCs). We found that XL413 addition during
SSTR editing in HSPCs slightly elevated SNP conversion at two
different loci, including the causative allele of sickle cell disease
(Fig. 4d, e and Supplementary Data 2). Short-term HSPC viability
was not grossly decreased by treatment with XL413 (Supplemen-
tary Fig. 4e). Taken together, we find that XL413 can increase
multiple forms of HDR in two primary cell types. Additional
work will be needed to determine the long-term effects of XL413
treatment to increase the edited fraction of cells if deployed in a
pre-clinical context.
CDC7 inhibition promotes homozygous HDR. Having tested
the ability of XL413 to increase the fraction of edited alleles in a
bulk population, we next evaluated whether XL413 increases the
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Fig. 2 Enhancing HDR by small molecule inhibition of factors discovered in genetic screening. a Schematic of small molecule evaluation. K562-BFP cells
were nucleofected with Cas9-RNPs targeting the BFP transgene and either plasmid dsDonor or oligonucleotide ssDonor templates. After electroporation
(EP), cells were added to media with or without compound. Cell populations were recovered into fresh media after 24 h and analyzed by flow cytometry
after 96 h. b CDC7 inhibition with XL413 significantly increases SSTR and HR. Shown is the percentage of GFP-positive cells by flow cytometric analysis of
K562-BFP cell populations 4 days post nucleofection with ssDonor (left) or dsDonor (right) comparing different chemical compound treatments. X-axis
indicates the intended molecular target of the small molecule inhibitors. c XL413 increases HDR in a concentration-dependent manner for both SSTR and
HR pathways. Shown is the percentage of GFP positive cells 4 days post nucleofection for editing with ssDonor (left) and plasmid dsDonor (right). Dashed
line indicates point where XL413 toxicity becomes significant. d Schematic showing strategies for pre-treatment and post-treatment with XL413. e Editing
outcomes in K562-BFP depend on timing of XL413 administration. Cells were untreated, treated for 24 h with XL413 before nucleofection (pre), treated for
24 h with XL413 after nucleofection (post) or both (pre- and post). Percentage of GFP positive cells was determined 4 days post nucleofection using flow
cytometry. All values are shown as mean ± SD (n= 3 biological replicates). Statistical significances were calculated by ordinary one-way ANOVA and
Dunnet’s multiple comparison test comparing different treatments to the control (adjusted p-values are reported as *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001). Source data are available in the Source Data file.
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Fig. 3 CDC7 inhibition increases HR and SSTR of diverse genetic cargoes in cell lines. a XL413 increases HR at endogenous loci with large HR donors.
K562 cells were nucleofected with Cas9-RNPs targeting six different genomic loci (SMC1A, LAMP1, NPM1, HIST2H2BJ, FUS, and TOMM20) with plasmid
dsDonor to knock-in a GFP sequence to the C-terminal end of the gene. Half of the pool of nucleofected cells was treated with 10 μM XL413 for 24 h while
the other half remained untreated. Flow cytometric analysis determined the percentage of GFP positive cells 3, 7, and 14 days after nucleofection. Gating
strategy depicted in Supplementary Fig. 3a. b XL413 increases SSTR at endogenous loci. K562 cells were nucleofected with RNP targeting TOMM20 and an
ssDonor encoding 2xFLAG (Supplementary Fig. 3b) in the presence or absence of 10 μM XL413 for 24 h, gDNA was extracted after 4 days, and SSTR
frequencies were determined by amplicon sequencing. c XL413 increases the frequency of SNP conversion. RNPs targeting five loci and ssDonors encoding
SNPs were introduced into cells and editing outcomes quantified as described in b. All values are shown as mean ± SD (n= 3 biological replicates).
Statistical significances were calculated by unpaired two-tailed t-test using the Holm-Sidak method (p-values are reported as *p < 0.05, **p < 0.01, ***p <
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frequency of multi-allelic editing on a per-cell basis. We per-
formed GFP-tagging in K562 cells at multiple loci as previously
described with or without XL413, fluorescently sorted single GFP-
expressing clones, and quantified knock-in alleles in each clone by
junction PCR (Supplementary Fig. 5a, b). We found that XL413
dramatically increased the frequency of homozygous HR even in
triploid K562 cells from undetectable to approximately 17% of
cells edited at the FUS and HIST1H2BJ loci. HDR at the SMC1A
locus was increased 4.9-fold such that almost all clones tested
were homozygous (Fig. 5a). Homozygous editing was also
increased up to 3.2-fold in T cells from healthy donor PBMCs, as
measured by a fluorescent reporter assay that mixes two linear
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dsDonor templates with different fluorophores (BFP or mCherry)
both targeted to the RAB11A locus22 (Fig. 5b and Supplementary
Fig. 5c, d). Our T-cell homozygous HDR assay only measures
integration of the two different fluorophores at a given locus (e.g.,
BFP+/mCherry+), and so these values likely undercount the true
frequency of biallelic editing by missing dual integration of the
same fluorophore (e.g., BFP+/BFP+). We therefore conclude that
CDC7 inhibition increases the rate of homozygous HDR, which
could be very useful for both research and therapeutic purposes.
CDC7 inhibition boosts HDR in multiple cell types. We pro-
filed XL413 in additional cell types at multiple loci, and found
that cells of different origins vary in the ability of XL413 to
increase HDR (Supplementary Fig. 6a). K562 cells, T cells, and
HSPCs are responsive to XL413, boosting all tested forms of HDR
up to 3.5-fold. Using XL413 in HEK293T, U-251, HeLa and
induced pluripotent stem cells (iPSCs) increased HDR at some
loci and with some donors, but not with others (Supplementary
Fig. 6a, b and Supplementary Data 2). XL413 did not increase
HDR in primary mouse glial cultures, primary human dermal
lymph endothelial cells (HDLECs) and primary human dermal
fibroblasts (HDFs). However, these cell types proliferate parti-
cularly slowly and CDC7 inhibition may not work in this context
(Supplementary Fig. 6a, c). Because XL413 is known to be non-
functional in a cell-type specific manner29, we tested other CDC7
inhibitors for their ability to increase HDR in contexts where
XL413 was inactive. The dual CDC7/CDK9 inhibitor PHA-
76749130 increased HR in K562 cells 2.3-fold and at two addi-
tional loci (1.5-fold and 1.7-fold) in HCT116 cells, which do not
respond consistently to XL413 (Supplementary Fig. 7a, b).
However, we found that treatment with PHA-767491 is more
toxic to cells than XL413 and that it results in a distinctly different
cell cycle profile than XL413 (Supplementary Fig. 7c–e). Overall,
we find that transcriptional inhibition of CDC7 (Supplementary
Fig. 2b, c) and two small molecule inhibitors of CDC7 can all
increase levels of HDR during Cas9 genome editing.
XL413 is more effective than other chemical HDR enhancers.
To contextualize the effectiveness of CDC7 inhibition, we com-
pared XL413 to other approaches previously reported to boost
HR. SCR7 inhibits NHEJ to rebalance DNA repair outcomes20,31,
RS-1 is a RAD51 agonist that activates recombination32,33,
L755507 is a β-3 adrenergic receptor agonist that works through
an unknown mechanism34, and i53 inhibits 53BP1 to reduce
NHEJ and favor recombination35. In our editing workflow, SCR7,
RS-1, and L755507 had little effect on HR (Fig. 6a, b). Combining
SCR7 or RS-1 with XL413 for 24 h also did not increase HR
beyond XL413 alone (Supplementary Fig. 8a) i53 peptide treat-
ment increased HR 1.5-fold when considering only the cells
expressing the plasmid encoding for i53 (Fig. 6c), which is
comparable to the 1.7-fold seen with XL413 in this experiment.
However, when determining the efficiency of i53 to increase HR
in the whole population of cells (Supplementary Fig. 8b) it is less
effective than XL413, and does not further increase editing in
combination with XL413 (Supplementary Fig. 8c).
XL413 treatment produces a transient cell cycle arrest. Expo-
sure of cells to CDC7 inhibitors, like XL413, has additional effects
on cells beyond increasing HDR. CDC7 is the catalytically active
subunit of DBF4-dependent kinase (DDK), which phosphorylates
and activates the MCM helicase to initiate the G1/S
transition36,37. XL413 has been reported to rapidly inhibit
phosphorylation of MCM2 and arrest cells in early S-phase23,38.
As timing of XL413 administration is important for its activity
(Fig. 2d, e), we investigated the overlap between XL413 stimula-
tion of HDR increase and cell cycle arrest. 24 h of XL413 treat-
ment causes inhibition of MCM2 phosphorylation as measured
by Western blot (Supplementary Fig. 9a) and cell cycle arrest
phenotypes as measured using a FUCCI live cell reporter sys-
tem39 and Hoechst33342 staining (Supplementary Fig. 9b–g).
Importantly, these effects are reversible and return to baseline 24
h after XL413 is removed. Post-editing treatment with XL413 for
24 h therefore synchronizes cells in S phase, and we speculate that
this extends the time cells spend in the HDR-permissive S/G2/M
phases of the cell cycle. Such a model would also explain why
dosing with XL413 before editing does not increase HDR, as the
cell cycle delay occurs before editing reagents are introduced.
Interestingly, treatment with other S-phase inhibitors such as
Aphidicolin or Hydroxyurea did not increase HR consistently
(Supplementary Fig. 9h) suggesting that cell cycle arrest with
XL413 is distinct from arrest with other S phase inhibitors.
The microtubule poison nocodazole has been previously
described to boost HDR by placing cells at a permissive point
in the cell cycle7, and we next compared nocodazole treatment to
XL413. In our hands, nocodazole increased HDR to a comparable
level as XL413 when cells were arrested with nocodazole prior to
editing (Fig. 6d). However, nocodazole has also been reported to
increase the frequency of aneuploidy and failed mitoses40–42. We
measured the frequency of cells with >4 N DNA content
produced by failed mitoses in compound-treated and untreated
cell cultures. We observed no significant increase in >4 N DNA
staining in untreated or XL413 treated cells after four days, but we
Fig. 4 CDC7 inhibition increases HR and SSTR in primary human cells. a XL413 increases HR at endogenous loci in T cells. Primary CD3+ T cells from two
healthy blood donors were nucleofected with RNPs targeting three different genomic loci (RAB11A, TUBA1B, and CLTA) with a linear dsDonor template to
knock-in a fluorescent reporter protein fused to the N-terminal end of the target protein. Nucleofected cells were treated with the indicated doses of XL413
for 24 h, then the percentage of reporter-positive T cells was quantified by flow cytometry 4 days after nucleofection. Gating strategy is depicted in
(Supplementary Fig. 4a). b XL413 increases SSTR at endogenous loci. Primary CD3+ T cells were nucleofected with RNPs targeting the indicated loci with
ssDonors to insert point mutations, treated with the indicated concentration of XL413 for 24 h. After 4 days, gDNA was extracted and SSTR and NHEJ
frequencies determined by amplicon sequencing. c XL413 increases the frequency of SNP conversion. RNPs targeting the CD4 locus and an ssDonor
encoding a naturally occurring SNP (Supplementary Fig. 4b–d) were introduced into T cells from three donors, and editing outcomes quantified by flow
cytometry after 4 days. Statistical significances were calculated by ordinary one-way ANOVA and Dunnet’s multiple comparison test (adjusted p-values
are reported as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). d XL413 increases the frequency of SNP conversion in the HBB gene in primary human
CD34+ HSPCs. RNPs targeting the HBB locus and an ssDonor encoding the E6V mutation25 were nucleofected into HSPCs in the presence or absence of
30 μM XL413, gDNA was extracted after 4 days, and mutation frequencies determined by amplicon sequencing. Statistical significances were calculated by
unpaired two-tailed t-test using the Holm-Sidak method (p-values are reported as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). e XL413 increases the
frequency of SSTR in primary human CD34+ HSPCs. Cells were nucleofected with RNPs targeting TOMM20 with a ssDonor that contains three
synonymous SNPs in the presence or absence of 30 μM XL413 for 24 h, gDNA was extracted after 4 days, and SSTR and NHEJ frequencies were
determined by amplicon sequencing. Values are shown as mean ± SD of the indicated number of samples. Source data are available in the Source Data file.
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found a significant increase in these events with nocodazole
treated samples (p < 0.001) (Fig. 6e, f).
In summary, we mined our HR and SSTR genetic dependency
datasets to identify CDC7 inhibition as a potent strategy to boost
HDR in human cell lines. XL413, a CDC7 inhibitor, improves the
efficiency of gene editing workflows for basic research or
therapeutic applications, increases gene replacement in multiple
cell types, and has utility in challenging contexts with therapeutic
potential such as primary T cells and HSPCs. CDC7 inhibition is
most effective when administered while editing is underway and
is thus maximally compatible with RNP-mediated gene editing
workflows.
Discussion
Our focused CRISPRi screen defined a network of genes that
contribute to Cas9-mediated HR from dsDonor templates.
Comparing networks of genes involved in HDR from different
donor templates (ssDonor vs. plasmid dsDonor) revealed that
many DNA repair factors are shared between SSTR and HR. The
most striking commonality is the shared dependence on the FA
pathway for both forms of repair. Despite this shared reliance on
the FA pathway, we also observed genetic differences between the
different types of HDR. Overall, this suggests that the early steps
of HDR may be similar for templated repair of a Cas9 break with
ssDonor or dsDonor, but the downstream stability and incor-
poration of different donor templates requires different factors.
Future work could expand this platform to genome-wide screens
or focus more narrowly on the FA pathway to determine if dif-
ferent FA sub-complexes act specifically during SSTR or HR.
By focusing on genes that restrict HDR and can also be tar-
geted by small molecule inhibitors, we identified CDC7 inhibition
as a strategy to boost HDR in human cells. We find that the small
molecule inhibitor, XL413, occupies the sweet spot among HDR
adjuvants of high efficacy, ease of use, and low toxicity. However,
XL413 is ineffective in some cell types29. Thus, XL413-resistant
cell lines could instead be treated with PHA-767491, if toxicity is
not a limiting factor. Future development may yield CDC7
inhibitors that combine the consistency of PHA-767491 and the
low toxicity of XL413.
As CDC7 plays a key role in DNA replication initiation, this
fits well into the intimate link between DNA repair and cell cycle
control43. CDC7 inhibition by XL413 both increases HDR and
delays cells in S phase. The most parsimonious explanation is that
XL413 promotes HDR by increasing the amount of time that cells
spend in the HDR-permissive S phase. However, this model is
partially at odds with observed stimulation of HDR with PHA-
767491 treatment, which arrests cells in G1 phase prohibiting
cells to move into S-phase38 (Supplementary Fig. 7e). This dif-
ferential cell cycle profile between XL413 and PHA-767491 could
potentially be explained by PHA-767491’s promiscuous activity
against other kinases such as Cdk9, which is required for S-phase
entry44,45. Another possibility is that CDC7 directly regulates
DNA repair, which would be consistent with reports that CDC7-
null yeast cells are sensitive to UV damage46. Mechanistic links
between CDC7 and DNA repair remain unexplored, but might
include direct phosphorylation of DNA repair proteins by CDC7.
For example, CDC7 has been reported to phosphorylate the
RAD18 ubiquitin ligase47, mutant alleles of which support
increased HDR rates48. REV7 is also a target of CDC7 and forms
a complex with shieldin to regulate DNA repair outcomes, and
thus inhibition of CDC7 could have an indirect effect on DNA
repair through REV749,50. Another possible mode of interaction
is scaffolding of DNA repair proteins by CDC7, which has been
reported for RAD1851. Better understanding of the links between
DNA replication control and DNA repair control may define
these mechanisms and suggest more targeted interventions, for
example preventing phosphorylation or degrading the key HDR-
regulating substrate of CDC7.
The general link between HDR stimulation and cell cycle
illustrates that HDR-boosting treatments can be a balancing act
between desired and undesired outcomes. It is tempting to wish
for a treatment that increases HDR to 100% efficiency, no matter
the mechanism. The microtubule poison nocodazole boosts HDR
in some contexts via G2/M arrest7, but also increases aneuploidy
and failed mitoses (Fig. 6d, e). Similarly, inappropriately acti-
vating DNA repair during mitosis leads to chromosome fusions52.
In our hands, CDC7 inhibition reversibly slows S-phase and
effectively promotes stable genetic changes without increasing the
rate of genomic instability. However, we cannot rule out that
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CDC7 inhibition has undesirable side-effects that remain to be
discovered. Thus, CDC7 inhibition to increase HDR in the con-
text of gene editing therapeutics warrants further investigation.
Here we demonstrate that understanding the genetics of gene
editing reactions can be used to design interventions that favor
certain types of DNA repair. While genetic CRISPR screens are a
powerful tool to uncover phenotypes directly related to the
expression levels of targeted genes, they fail to determine phe-
notypic outcomes that are caused by post-translational mod-
ifications. We anticipate that further work to map fundamental
DNA repair pathways including studying the effects of post-
translational changes of DNA repair proteins will suggest new
strategies and targetable regulators to increase the precision and
the efficacy of gene editing workflows.
Methods
Pooled screen. Replicate cultures of K562 cells stably expressing a dCas9-KRAB
construct and a cassette containing a BFP reporter and a guide RNA targeting a
library of DNA repair factors (Supplementary Data 1 GUIDES and previously
described9) were thawed, cultured, and puromycin treated. 10e+06 cells from each
replicate were subcultured (UNZAP). 25e+06 cells from each replicate were har-
vested for nucleofection. Each nucleofection aliquot was spun down, washed in
PBS, and resuspended in 825 ml of nucleofection buffer SF (Lonza, Basel, Swit-
zerland). Two hundred and seventy-five microliter of RNP editing mixture was
added and mixed by pipetting. RNP for each replicate contained 2000 pmoles of
sgRNA, 1,650 pmoles of Cas9, and 220 mg of plasmid pCR1075 donor DNA in
Cas9 buffer (20 nM HEPES [pH 7.5]), 150 mM KCl, 1 mM MgCl2, 10% glycerol,
and 1 mM TCEP). Each replicate of the RNP cell slurry was split and nucleofected
in parallel in a Lonza 96-well Shuttle nucleofector (code FF-120), re-pooled, and
cultured for two (replicate 1) or three (replicate 2) days. Nucleofected replicates
were sorted into GFP+ (GFP) and non-fluorescent (NON) populations on a Sony
SH800S sorter. In parallel, an 85e+06 cell aliquot was harvested from each non-
electroporated population the day of the sort (UNZAP), and an 85e+06 cell aliquot
was harvested from each nucleofected cell library on the day of sorting (PRE-
SORT). Harvested and sorted populations were spun down, rinsed in PBS, and
frozen at −80 °C.
DNA from each cell population: PREZAP, UNZAP, PRESORT, GFP, and NON
(non-treated) was purified using Machery-Nagel Blood Purification kits and the
total amount of DNA quantified. One microgram of genomic DNA was amplified
per Phusion HiFi PCR reaction using primers specific to the gRNA cassette as
described45. Up to 24 PCR reactions were set up for each cell population to obtain
desired coverage of the cell library. The thermocycler was set for one cycle of 98 °C
for 30 s, 25 cycles of 98 °C for 15 s, 56 °C for 15 s, and 72 °C for 15 s, and one cycle
of 72 °C for 10 min and held at 4 °C. PCR reactions were pooled, purified using
SPRI beads, and sized on an agarose gel. Amplified DNA from each cell population
was normalized to input cell numbers, purified a second time using SPRI beads,
and sequenced on a HiSeq2500 (Illumina).
Pooled screen analysis. Data analysis was performed as described11. Briefly,
sequence reads were trimmed, aligned to DNA Repair Guide Sequences (Supple-
mentary Data 1 GUIDES) and quantified. Read counts for each gRNA were nor-
malized and compared to the distribution of untargeted control guides to
determine significance and log2 magnitude of change. The top three guide-level
phenotypes were collapsed to produce gene-level phenotype score. Results for the
GFPvPRE comparison are available in (Supplementary Data 1).
Pooled screen phenotype comparison. The magnitude of gene-level phenotype
scores (calculated above) varied between screens. To facilitate direct comparison of
essential genes between HR and SSTR results, essential genes (phenotype scores <
0) were unity normalized against all essential gene phenotype scores for the ori-
ginating screen, such that Z= (phenotype_score − min(dataset))/(max(dataset)-
min(dataset)). The resulting normalized values ranged from 0 (strongest phenotype
score) to 1 (weakest phenotype score). Z values were binned for display purposes:
bin 1, 0.0–0.2; bin 2, 0.2–0.4; bin 3, 0.4–0.6; bin 4, 0.6–0.8; and bin 5, 0.8–1.0. FA
and related genes from either screen (FAAP20, UHRF1, TIP60, POLQ, and LIG4)
with a phenotype score > 0 were assigned to bin 5. Raw data from this figure is
presented in (Supplementary Data 1).
Pooled screen GO-term comparison. Data from SSTR9 and HR (this manuscript)
screens was filtered for statistical significance (p > 0.05) and separated into two
categories: genes involved in SSTR or genes involved in HR. The gene list for each
category was compared to the starting guide pool used in our screens (Supple-
mentary Data 1 GUIDES) using DAVID v6.814. Default search categories were
used. Gene lists for GO categories are reported in (Supplementary Data 1 GO
Terms).
siRNA transfection. Approximately 1e+05 suspension or adherent cells were
reverse transfected into 24-well plates using RNAiMAX (Thermo Fisher). siRNA
(Supplementary Data 3) dosage was 40 nM. Cells were siRNA treated for 48 h,
harvested, nucleofected, and recovered into media lacking siRNA. Verification of
knockdown was performed at the time of nucleofection via qPCR. Cells were
harvested for flow cytometry 4 days post nucleofection.
Cell lines and culture. HEK293, HCT116, HeLa, U251, and K562 cells were
acquired from the UC Berkeley Tissue Culture Facility. HEK293, HCT116, and
HeLa cells were maintained in DMEM medium supplemented with 10% fetal
bovine serum and Penicillin/Streptomycin. K562 cells were maintained in RPMI
medium supplemented with 10% fetal bovine serum and Penicillin/Streptomycin.
U251 cells were maintained in DMEM-F12 medium supplemented with 10% fetal
bovine serum and Penicillin/Streptomycin. Cell lines were tested regularly for
mycoplasma contamination using enzymatic (Lonza, Basel, Switzerland) and PCR-
based assays (Bulldog Bio, Portsmouth, New Hampshire). Primary mouse glial cells
were extracted as described53 and maintained in DMEM medium supplemented
with only 10% fetal bovine serum. Human dermal lymphatic endothelial cells
(HDLECs) were maintained in EBM-2 MV media from Lonza. Human iPSCs were
generated from dermal fibroblasts from a healthy male subject (WTc) using the
episomal reprogramming method54. iPSCs were cultured in Stemfit (Ajinomoto)
on matrigel coated plates at 37 °C. After passaging, iPSCs were plated in Stemfit
with Rock inhibitor Y-27632 (SelleckChem). Human dermal fibroblasts (HDFs)
were derived from a healthy male subject and cultured in DMEM supplemented
with 1% sodium pyruvate (Thermo Fisher), 10% fetal bovine serum and Penicillin/
Streptomycin. Derivation and use of human iPSCs and HDFs was approved by the
UCSF Committee on Human Research, San Francisco, CA (IRB 10-02521). All
subjects provided written informed consent prior to participation. Cryopreserved
wildtype human mobilized peripheral blood CD34+ HSPCs from volunteer donors
were purchased from Allcells, and were cultured in SFEMII+ CC110 (StemCell
Technologies).
Fig. 6 Comparisons between XL413 and other small molecule HDR-boosting strategies in K562 cells. a Direct comparison between XL413 and RS1 or
SCR7. Cells were nucleofected with RNP targeting the LAMP1 or FBL loci with dsDonors encoding C-terminal fusions to GFP, cultured in XL413 (33 μM),
SCR7 (1 μM) or RS-1 (10 μM) for 24 h, and editing rates were measured 4 days post nucleofection by flow cytometry. b Comparison between XL413 and
L755507. Cells were nucleofected with RNPs targeting the RAB11A, LAMP1, or TOMM20 loci with dsDonors encoding N-terminal (RAB11A) or C-terminal
(LAMP1, TOMM20) fusions to GFP, cultured in XL413 (10 μM) or L755507 (5 μM) for 24 h, and editing rates were measured 4 days post nucleofection by
flow cytometry. c Comparison between XL413 and i53. Cells were nucleofected with RNP targeting the RAB11A locus with dsDonor encoding an N-terminal
fusion to GFP. i53-treated samples were lipofected with (3 μg) plasmid encoding i53 and BFP 24 h prior to nucleofection with editing reagents. XL413-
treated samples were cultured in 10 μM XL413 for 24 h after nucleofection, then editing outcomes were measured 4 days post-nucleofection by flow
cytometry. i53-transfected cells were gated using a BFP fluorescent marker expressed from the i53 expression plasmid. d Direct comparison between
XL413 and nocodazole. Cells were nucleofected with RNP targeting the RAB11A, LAMP1, TOMM20, or FBL loci with dsDonors encoding N-terminal (RAB11A)
or C-terminal (LAMP1, TOMM20, and FBL) fusions to GFP. Samples were treated with nocodazole (33 ngmL−1) for 24 h before nucleofection. XL413-
treated samples were cultured in 10 μM XL413 for 24 h after nucleofection. Editing rates were measured 4 days post-nucleofection by flow cytometry.
e 1Cells were treated with nocodazole or XL413 for 24 h and then released into normal media for four days prior to propidium iodide staining and flow
cytometry. Example plots are shown for untreated, nocodazole, and XL413 treated samples. f Quantification of frequency of cells with a > 4 N DNA content
(indicative of failed mitoses) from e. All values are shown as mean ± SD (n= 3 biological replicates). Statistical significances were calculated by ordinary
one-way ANOVA and Dunnet’s multiple comparison test (adjusted p-values are reported as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Source
data are available in the Source Data file.
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T Cell isolation and culture. Primary human T cells were isolated from two de-
identified healthy human donors from residuals from leukoreduction chambers
after Trima Apheresis (Vitalant), with written informed consent under a protocol
approved by the UCSF IRB (BU101283). Peripheral blood mononuclear cells
(PBMCs) were isolated by Ficoll centrifugation using SepMate tubes (STEMCELL,
per manufacturer’s instructions), then T cells were further isolated from PBMCs by
magnetic negative selection using an EasySep Human T Cell Isolation Kit
(STEMCELL, per manufacturer’s instructions). Isolated T cells were cultured at 1
million cells mL−1 in XVivo15 medium (STEMCELL) with 5% fetal bovine serum,
50 μM 2-mercaptoethanol, and 10 mM N-Acetyl L-Cystine, and stimulated for
2 days prior to electroporation with anti-human CD3/CD28 magnetic dynabeads
(ThermoFisher) at a beads to cells concentration of 1:1, along with a cytokine
cocktail of IL-2 at 200 U mL−1 (UCSF Pharmacy), IL-7 at 5 ng mL−1 (Thermo-
Fisher), and IL-15 at 5 ng mL−1 (Life Tech). T cells were harvested from their
culture vessels and magnetic dynabeads were removed by placing cells on an
EasySep cell separation magnet for 5 min. Immediately prior to electroporation, de-
beaded cells were centrifuged for 10 min at 90 g, media aspirated, and resuspended
in the Lonza electroporation buffer P3 using 20 µL buffer per one million cells.
Cas9, RNA, and donor DNA preparation. Streptococcus pyogenes Cas9 (pMJ915,
Addgene #69090) with two nuclear localization signal peptides and an HA tag at
the C-terminus was expressed in Rosetta2 DE3 (UC Berkeley Marcolab) cells. Cell
pellets were sonicated, clarified, Ni2+ -affinity purified (HisTraps, GE life sci-
ences), TEV cleaved, cation-exhanged (HiTrap SP HP, GE life sciences), size
excluded (Sephacryl S-200, GE life sciences) and eluted at 40 in 20 mM HEPES
KOH pH 7.5, 5% glycerol, 150 mM KCl, 1 mM dithiothreitol (DTT)55. Alter-
natively, Streptococcus pyogenes Cas9-NLS was obtained from the QB3 MacroLab
at UC Berkeley.
sgRNAs were synthesized by Synthego as modified gRNAs with 2′-O-methyl
analogs and 3′ phosphorothioate internucleotide linkages at the first three 5′ and 3′
terminal RNA residues using protospacer sequences described in (Supplementary
Data 3).
crRNAs/tracrRNAs were chemically synthesized (Edit-R, Dharmacon Horizon)
using protospacer sequences described in (Supplementary Data 3).
ssDonors were obtained by ordering unmodified Ultramer oligonucleotides
(Integrated DNA Technologies).
dsDonor was obtained by purifying plasmid DNA from bacterial cultures
containing the indicated plasmid (Qiagen) or by SPRI purification of long double-
stranded PCR amplicons.
Plasmid constructs. Sequences for plasmids used in this study are described in
(Supplementary Data 3). AICSDP-8:TOMM20-mEGFP, AICSDP-19:LAMP1-
mEGFP, AICSDP-13:FBL-mEGFP, AICSDP-50: NPM1-mEGFP, AICSDP-57:
SMC1A-mEGFP, AICSDP-64: FUS-mEGFP, AICSDP-52: HIST1H2BJ-mEGFP
were gifts from The Allen Institute for Cell Science (Addgene plasmid #s 87423,
101782, 87427, 109122, 114406, 114410, and 109121). pCR1063, pCR1068, and
BFP dest clone were gifts from Jacob Corn (Addgene plasmid #s 111091, 111092,
71825).
Cas9 RNP assembly and nucleofection. Fifty pmoles of sgRNA was diluted using
Cas9 buffer (20 nM HEPES [pH 7.5]), 150 mM KCl, 1 mM MgCl2, 10% glycerol,
and 1 mM TCEP) or water. 1.25 μL of 40 mM Cas9-2xNLS (50 pmoles) was slowly
mixed in, and the resulting mixture was incubated for 5 min at room temperature
to allow for RNP formation. After incubation, either 0.5 μL of 100 μM ssDonor or
1.5 or 2 μg of plasmid DNA was introduced and mixed by pipetting. The total
volume of RNP solution was 5 ml, where the volume of Cas9 buffer was adjusted to
account for volume differences between ssDonor and plasmid DNA. Between 1e
+05 and 2e+05 cells were harvested, washed once in PBS, and resuspended in 15
μL of nucleofection buffer (Lonza, Basel, Switzerland). Five microliter of RNP
mixture was added to 15 μL of cell suspensions. Reaction mixtures were electro-
porated in Lonza 4D nucleocuvettes, incubated in the nucleocuvette at room
temperature for five minutes, and transferred to culture dishes containing pre-
warmed media. Large-scale nucleofections were performed by splitting cultures and
conducting multiple parallel nucleofections.
Editing outcomes were measured four days post-nucleofection by flow
cytometry or by amplicon sequencing (see below). Resuspension buffer and
electroporation conditions were the following from each cell line: K562 in buffer SF
with FF-120, HEK293 in buffer SF with DS-150, T cells in buffer P3 with EH-115,
primary mouse glial cells in buffer P3 with DS-112, HDLECs in buffer P3 with CA-
137 HCT116s in buffer SE with EN-113, and HeLa cells in buffer SE with CN-114,
U251 cells in buffer SE with DS130, iPSCs in buffer P3 with DS-138, HDFs in
buffer P3 with DS-150 and HSPCs in buffer P3 with ER-100.
Unless otherwise indicated, cells were separated into three stocks, then
nucleofected, recovered, and analyzed separately (biological triplicate).
T Cell nucleofections. RNPs were generated immediately prior to electroporation.
Briefly, crRNA targeting RAB11A, TUBA1B, CLTA, exon 6 of CD4, or five genomic
loci (Chr5GD1, Chr5GD2, CD55_1, CD55_2, and CD59_2) and tracrRNAs were
chemically synthesized (Edit-R, Dharmacon Horizon), and Cas9-NLS was
recombinantly produced and purified (QB3 Macrolab). Lyophilized RNA was
resuspended in 10 mM Tris-HCL (7.4 pH) with 150 mM KCl at a concentration of
160 µM, and stored in aliquots at −80 °C. crRNA and tracrRNA aliquots were
thawed, mixed 1:1 by volume, and annealed by incubation at 37 °C for 30 min to
form an 80 µM gRNA solution. This was further mixed 1:1 by volume with 40 µM
Cas9-NLS protein to achieve a 2:1 molar ratio of gRNA:Cas9, with final RNP
concentration of 20 µM. Long linear dsDonor templates creating an N-terminal
fusion protein of a fluorescent protein (GFP, BFP or mCherry) and the Rab11a,
Tubulin, or Clathrin Light Chain A proteins22 were generated as a PCR amplicon
using KapaHiFi polymerase (Kapa Biosystems), purified by SPRI bead cleanup, and
resuspended in water to 125 ng µL−1 as measured by light absorbance on a
NanoDrop spectrophotometer (Thermo Fisher). For CD4 SNP introduction,
ssDonor templates were synthesized by IDT Technologies encoding the dbSNP:
rs28919570 in-frame missense mutation (NM_000616.5c.793C>T, p.Arg265Trp).
All ssDonor sequences are listed in (Supplementary Data 3).
Fifty picomolar of RNP and 0.25 μg of dsDonor, or 100 pmol of ssDonor, were
mixed for 5–10 min, then added to cells 3–5 min before electroporation. One
million T cells per well with RNP and donor template were electroporated using
the Lonza 4D 96-well electroporation system with pulse code EH115, in biological
replicate of n= 2–3. Immediately post-electroporation, prewarmed media was
added to rescue the cells then each electroporation condition was split into 5 wells
of a 96-well U-bottom tissue culture plate. Electroporated cells were incubated at 1
million cells mL−1 in final volume 200 μL media with IL-2 at 500 U mL−1 and
increasing concentrations of XL413. After 24 h, all cells were washed in PBS, and
fresh media was added containing only IL-2 at 500 U mL−1. Approximately 3 days
post-electroporation, cells were collected by centrifugation at 300 × g, media
discarded, and antibody stains were added (UCHT1-CD3-PE, OKT4-CD4-PE-Cy7,
RPA-T8-APC (all from BioLegend), and GhostDye780 (Tonbo)) for 20 min
(Supplementary Data 3). To assess conversion to the CD4SNP sequence, SK3-CD4-
FITC (Biolegend) was also added to the antibody staining. Cells were washed,
resuspended in PBS+ 1% serum (120 μL per well), and then an equal volume (80
μL) of each well was sampled using an Attune NxT Focusing Flow Cytometer with
Autosampler attachment (ThermoFisher).
Genomic DNA extraction (for amplicon sequencing). Approximately 1e+05
cells were harvested and resuspended in 50 μL of QuickExtract DNA extract
solution (Lucigen). Reactions were incubated for 20 min at 65 °C and 5min at
95 °C. Extractions were diluted 1:4 with dH2O, spun for 5 min at max speed in
a microcentrifuge, and the supernatants retained for downstream analysis.
PCR amplification of edited regions. PCR reactions were generated from 2× Q5
master mix (NEB), primers (Supplementary Data 3) at 500 nM, and 5 μL of
genomic DNA (see above). Unless otherwise noted, PCR primers have a 5′
sequence tag (GCTCTTCCGATCT) that allows re-amplification for Illumina
sequencing (amplify-on PCR). The thermocycler was set for one cycle of 98 °C for
1 min, 35 cycles of 98 °C for 10 s, 63 °C for 15 s, 72 °C for 60 s, and one cycle of
72 °C for 4 min, and held at 4 °C. PCR amplicons were purified using SPRI beads,
run on a 1.5% agarose gel to verify size and purity, and quantified by Qubit
(Thermo Fisher, Waltham, MA).
NGS library generation and sequencing. Illumina adapters and index sequences
were added to 100 ng of purified PCR amplicons by amplify-on PCR. Amplify-on
was performed using 100 ng of template DNA, 0.5 μM of forward/reverse primers,
and 2× Q5 Master Mix (NEB). The thermocycler was set for one cycle of 98 °C for
30 s, 16 cycles of 98 °C for 10 s, 62 °C for 20 s, 72 °C for 30 s, and one cycle of 72 °C
for 1 min, and held at 4 °C. Each adapter-conjugated amplicon was quantified by
qubit, normalized, and pooled at equimolar amounts. Pooled samples were purified
using SPRI beads. Library size and purity was verified by Bioanalyzer trace prior to
sequencing on an Illumina MiSeq using reagent kit v3 (2 × 300 bp).
NGS analysis of amplicons. Samples were deep sequenced on an Illumina MiSeq
at 300 bp paired-end reads to a depth of at least 10,000 reads per sample. Cortado
(https://github.com/staciawyman/cortado v1.0) was used to analyze editing out-
comes. Briefly, reads were adapter trimmed then joined before performing a global
alignment between reads and the reference and donor sequences using NEEDLE56.
Rates of HDR are calculated as total number of reads that are successfully con-
verted to the donor sequence (and have no insertions or deletions at the cut site)
divided by the total number of aligned reads. NHEJ rates are calculated as any
reads where an insertion or deletion overlaps the cut site or occurs within a six base
pair window around the cut site divided by the total number of aligned reads.
SSTR/HDR rates were calculated at specific regions by counting total number of
reads with flag occurrence divided by the number of aligned reads. Amplicon
sequencing results can be found in (Supplementary Data 2).
Compound treatment. Acyriaflavin A, XL413, Aphidicolin, GW843682X,
L755507, PHA-767491, and Ro3280 were sourced from Tocris. Hydroxyurea, A64
trifluoroacetate, GKT136901, SB220025, nocodazole, and UNC2170 tri-
fluoroacetate were sourced from Sigma.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-15845-1
12 NATURE COMMUNICATIONS |         (2020) 11:2109 | https://doi.org/10.1038/s41467-020-15845-1 | www.nature.com/naturecommunications
Approximately 1e+05 suspension or adherent cells were seeded post-
nucleofection into 96-well plates in media supplemented with the following
concentrations of compounds: Acyriaflavin A at 5 μM, XL413 at 33 μM,
Hydroxyurea at 2 μM, SRC7 at 1 μM, RS1 at 10 μM, Aphidicolin at 2 mgmL−1,
A64 trifluoroacetate at 1 μM, SB220025 at 0.5 μM, GKT136901 at 50 μM,
GW843682X at 0.5 μM, Ro3280 at 100 nM, UNC2170 trifluoroacetate at 150 μM,
nocodazole at 33 ng μL−1, and L755507 at 5 μM. Cells were compound treated for
24 h, harvested, washed, and recovered into fresh media. Cells were harvested for
flow cytometry or amplicon sequencing 4 days post nucleofection. Nocodazole
treatments were administered as compound-treated media 24 h pre-nucleofection
instead of post-nucleofection.
i53 treated cells were transfected using Lipofectamine 2000 from Invitrogen.
Three microgram of each of three plasmids containing a broken i53 gene (Addgene
#94939), an intact i53 gene (Addgene #74940), and both an intact i53 gene and a
BFP reporter (Addgene #111145, respectively, were incubated in OPTI-MEM with
Lipofectamine 2000 for 30 min. The cells were then incubated with the
Lipofectamine plasmid solution for 24 h, pre-nucleofection. The BFP reporter was
used to analyze the transfection efficiency of the i53 plasmid into the cells by flow
cytometry.
qPCR. Between 1e+05 and 2e+05 cells were harvested and RNA extracted using
Qiagen RNeasy kits (Qiagen, Venlo, Netherlands). cDNA was produced from 1mg
of purified RNA using the iScript Reverse Transcription Supermix (Bio-Rad).
qPCR reactions were performed using the SsoAdvanced Universal SYBR Green
Supermix (Bio-Rad) in a total volume of 10 mL with primers at final concentrations
of 500 nM. The thermocycler was set for 95 °C for 2 min and 40 cycles of 95 °C for
2 s and 55 °C for 8 s. Fold enrichment of the assayed genes over the control ACT1B
and/or GAPDH loci were calculated using the 2−ΔΔCt method essentially as
described57. Primer sequences can be found in Supplementary Data 3.
Western blotting. Cells were harvested and washed with PBS. Cell were lysed in
1× RIPA buffer (EMD Millipore) for 10 min on ice. Samples were spun down at
14,000 × g for 15 min, and cleared protein lysates were transferred to a new tube.
Twenty milligram of RIPA protein lysate was resolved on a TGX anyKD gel (Bio-
Rad) and semi-dry transferred (TransBlot Turbo, Bio-Rad) to nitrocellulose
membranes. Membranes were blocked in 5% milk, incubated with primary anti-
bodies in 5% milk, incubated with secondary antibodies in 5% milk, and exposed
on a LiCor Odyssey CLx (Li-Cor). Antibodies used were: FLAG (Sigma F1804,
1:1000), GAPDH (cell Signaling 97166, 1:5000), phospho-S53 MCM2 (Abcam
ab109133, 1:1000), MCM2 (Abcam ab6153, 1:1000), 1:10,000 donkey anti-mouse
IgG-IR800 (Li-Cor 925-32212), 1:10,000 donkey anti-mouse IgG-IR680 (Li-Cor
925-68022), 1:10,000 donkey anti-rabbit IgG-IR800 (Li-Cor 925-32213), 1:10,000
donkey anti-rabbit IgG-IR680 (Li-Cor 925-68023).
Biallelic editing assays. To check for frequencies of multi-allelic knock-ins in
K562 cells, cells were nucleofected with RNPs targeting FUS, HIST1H2BJ or
SMC1A and corresponding dsDonors, respectively, and were kept in complete
media or media treated with 10 μM XL413 for 24 h. After 24 h the drug was
removed and cells cultured for an additional 3 days. Four days of post nucleo-
fection cells were analyzed for GFP fluorescence using an Aria II (BD Biosciences)
cell sorter. GFP positive cells in both treated and untreated samples were sorted as
single cells into 96-well culture plates containing complete media. Single-cell clones
were grown for 10 days and DNA was extracted using a QuickExtract DNA
extraction buffer (Lucigen). PCR across the C-terminal insertion site was per-
formed using Q5 polymerase (New England Biolabs). Primers for PCRs can be
found in Supplementary Data 3. PCR products were run on a 1% agarose gel and
genotypes were determined. Clones classified as heterozygotes showed both the
wild-type and knockin PCR band and clones classified as homozygotes only
showed the knock-in PCR band (higher molecular weight). Clones that only
showed the wildtype band are named no knock-in but could be considered as
clones that show integration of the GFP sequence somewhere else in the genome
(as they were in the GFP positive cell pool but do not show integration at the target
site). In some clones we observed deletional bands. These clones were excluded in
our analysis.
To quantify biallelic editing rates in T cells, cells were nucleofected with RNPs
targeting the RAB11A locus as described above but with two different dsDonor
constructs in a 1:1 ratio, one of which contains a BFP reporter sequence and one of
which contains an mCherry reporter. Cells were treated with increasing amounts
(0, 3.3, 10, and 33 μM) of XL413. After 4 days cells were analyzed for successful
knock-in by flow cytometry and frequencies of double positive cell populations
(BFP+ and mCherry+) were determined that represent the biallelic knock-in rates.
FUCCI cell line generation. K562 cells were electroporated with 40 µg pML143
donor vector containing EF1α-mAG1-geminin(1–110)-P2A-mKO2-hCdt1
(30–120) flanked by homology arms to AAVS1/PPP1R12C locus and 5 µg each of
AAVS1L and AAVS1R TALENs. Targeted cells were sorted by FACS into 96-well
plates to isolate single clones. Clonal cell lines were assayed by live cell imaging and
flow cytometry to verify correct correlation with fluorescence and cell cycle
progression.
Cell cycle assay/DNA quantification assay. K562 FUCCI cells were grown in
complete RPMI containing Aphidicolin (2 mgmL−1), Hydroxyurea (2 mM) or
XL413 (33 μM). Cells were harvested at indicated time points and subjected to flow
cytometry. Cell cycle status was determined gating for mAG1+/mKO2−(S/G2/M),
mKO2+/ mAG1− (G1), mAG1+/ mKO2+ (early S) and mAG1−/mKO2− (early
G1) cell populations. DNA content of the cells was determined using
Hoechst33342 (Thermo Fisher) DNA dye. Hoechst33342 was added to cells in
culture medium (final concentration 1 mgmL−1) for 30 min at 37 °C before cells
were subjected to flow cytometry.
Cell cycle analysis was also performed by PI staining with flow cytometry. Cells
were incubated in 0.5 % Triton X-100 in PBS, treated with RNase A, stained with 5
μL propidium iodide (1 mgmL−1) and analyzed by flow cytometry.
Addgene constructs. A full list of reagents used in this manuscript can be found
in Supplemental Data 3. BFP dest clone was a gift from Jacob Corn (Addgene
plasmid # 71825; http://n2t.net/addgene:71825; RRID:Addgene_71825). AICSDP-
19:LAMP1-mEGFP was a gift from The Allen Institute for Cell Science (Addgene
plasmid # 101782; http://n2t.net/addgene:101782; RRID:Addgene_101782).
AICSDP-13:FBL-mEGFP was a gift from The Allen Institute for Cell Science
(Addgene plasmid # 87427; http://n2t.net/addgene:87427; RRID:Addgene_87427).
AICSDP-8:TOMM20-mEGFP was a gift from The Allen Institute for Cell Science
(Addgene plasmid # 87423; http://n2t.net/addgene:87423; RRID:Addgene_87423).
AICSDP-50: NPM1-mEGFP was a gift from The Allen Institute for Cell Science
(Addgene plasmid # 109122; http://n2t.net/addgene:109122; RRID:
Addgene_109122). AICSDP-57: SMC1A-mEGFP was a gift from The Allen
Institute for Cell Science (Addgene plasmid # 114406; http://n2t.net/
addgene:114406; RRID:Addgene_114406). AICSDP-64: FUS-mEGFP was a gift
from The Allen Institute for Cell Science (Addgene plasmid # 114410; http://n2t.
net/addgene:114410; RRID:Addgene_114410). AICSDP-52: HIST1H2BJ-mEGFP
was a gift from The Allen Institute for Cell Science (Addgene plasmid # 109121;
http://n2t.net/addgene:109121; RRID:Addgene_109121).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequencing reads used in the pooled screen and amplicon sequencing data were
deposited in SRA as PRJNA610420. Plasmid constructs are described in Supplementary
Data 3. All other relevant data are available from the authors upon reasonable request.
Code availability
Code used for amplicon sequencing data processing is available at https://github.com/
staciawyman/cortado.
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